Immune Therapies in AL Amyloidosis—A Glimpse to the Future
Cancers · 22.04.2024 · 16 (8) · 1605
DOI: 10.3390/cancers16081605 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 22.04.2024. Verfasst von Arnon Haran und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Hadassah Hebrew University Medical Center, Jerusalem 91120, Israel. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Light-chain (AL) amyloidosis is a rare plasma cell disorder characterized by the deposition of misfolded immunoglobulin light chains in target organs, leading to multi-organ dysfunction. Treatment approaches have historically mirrored but lagged behind those of multiple myeloma (MM). Recent advancements in MM immunotherapy are gradually being evaluated and adopted in AL amyloidosis. This review explores the current state of immunotherapeutic strategies in AL amyloidosis, including monoclonal antibodies, antibody–drug conjugates, bispecific antibodies, and chimeric antigen receptor T-cell therapy. We discuss the unique challenges and prospects of these therapies in AL amyloidosis, including the exposure of frail AL amyloidosis patients to immune-mediated toxicities such as cytokine release syndrome (CRS) and immune effector-cell-associated neurotoxicity syndrome (ICANS), as well as their efficacy in promoting rapid and deep hematologic responses. Furthermore, we highlight the need for international initiatives and compassionate programs to provide access to these promising therapies and address critical unmet needs in AL amyloidosis management. Finally, we discuss future directions, including optimizing treatment sequencing and mitigating toxicities, to improve outcomes for AL amyloidosis patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Hadassah Hebrew University Medical Center, Jerusalem 91120, Israel.
- Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva 49100, Israel.
ORCID-Profile: Moshe E Gatt
Zitieren
APA
Haran, A., Vaxman, I., Gatt, M. E., & Lebel, E. (2024). Immune Therapies in AL Amyloidosis—A Glimpse to the Future. Cancers, 16(8), 1605. https://doi.org/10.3390/cancers16081605
Vancouver
Haran A, Vaxman I, Gatt ME, Lebel E. Immune Therapies in AL Amyloidosis—A Glimpse to the Future. Cancers. 2024;16(8):1605. doi:10.3390/cancers16081605
BibTeX
@article{Haran2024,
author = {Haran, Arnon and Vaxman, Iuliana and Gatt, Moshe E and Lebel, Eyal},
title = {Immune Therapies in AL Amyloidosis—A Glimpse to the Future},
journal = {Cancers},
year = {2024},
volume = {16},
number = {8},
pages = {1605},
doi = {10.3390/cancers16081605}
}
EUVIMED